Dabigatran versus Acenocumarol for the Prevention of Stroke in Atrial Fibrillation. Budget Impact Analysis in one Health Department in Spain

Background: To Estimate, in the context of a Health Department of the Valencia Health Agency, the budgetary impact of the widespread use of dabigatran at doses of 110 and 150 mg in patients with non-valvular atrial fibrillation (AF), regarding the current scenario with acenocoumarol therapy. Methods...

Descripción completa

Detalles Bibliográficos
Autores: Pla, AB, Sóler, VG, Ridao-López, M, Pérez, JN, Cubells, BN, Peiró, S
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2013
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:dnet:r-fisabio___::8e571857ebe50f7597f04703c7d296de
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/21081
Access Level:acceso abierto
Palabra clave:Anticoagulant
Dabigetran
Acenocoumarol
Health Care Costs
Atrial fibrillation
Economics
id ES_f4eeeba0e22cc140905f7ceb58bfa2f9
oai_identifier_str oai:dnet:r-fisabio___::8e571857ebe50f7597f04703c7d296de
network_acronym_str ES
network_name_str España
repository_id_str
spelling Dabigatran versus Acenocumarol for the Prevention of Stroke in Atrial Fibrillation. Budget Impact Analysis in one Health Department in SpainPla, ABSóler, VGRidao-López, MPérez, JNCubells, BNPeiró, SAnticoagulantDabigetranAcenocoumarolHealth Care CostsAtrial fibrillationEconomicsBackground: To Estimate, in the context of a Health Department of the Valencia Health Agency, the budgetary impact of the widespread use of dabigatran at doses of 110 and 150 mg in patients with non-valvular atrial fibrillation (AF), regarding the current scenario with acenocoumarol therapy. Methods: Budget impact analysis of three scenarios of oral anticoagulation use in AF: a) current treatment with acenocoumarol, b) widespread replacement of acenocoumarol for Dabigatran 110 mg and, c) idem at doses of 150 mg. The analysis was conducted from the perspective of the Valencia Health Agency with a time horizon of one year (2009). The effectiveness and adverse effects were extrapolated from the RE-LY study, while prevalence and cost data correspond to the Health Department estimates in 2009. Results: We included 5889 patients (2.4% of the population > 18 years) diagnosed with AF, of which 3726 (63.2%) were treated with acenocoumarol. The total costs of each scenario were (sic) 1,119,412 (sic) 300 patient/year) for acenocoumarol, (sic) 4,985,095 (sic) 1,337 patient/year) for dabigatran 110 and (sic) 4,981,226 ((sic) 1,336 patient/year) for dabigatran 150, with a budget impact of 1,037 euros/year per patient shifted from acenocumarol to dabigatran-150. Conclusions: The high budgetary impact of moving to a scenario of widespread substitution of warfarin for Dabigatran supports the restriction of this therapeutic strategy to subgroups of patients at high risk or difficult control.MINISTERIO DE SANIDAD Y CONSUMO2013info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/21081Revista Espanola de Salud PublicaISSN: 11355727ISSNe: 21739110reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Españolinfo:eu-repo/semantics/openAccessoai:dnet:r-fisabio___::8e571857ebe50f7597f04703c7d296de2026-06-11T12:45:17Z
dc.title.none.fl_str_mv Dabigatran versus Acenocumarol for the Prevention of Stroke in Atrial Fibrillation. Budget Impact Analysis in one Health Department in Spain
title Dabigatran versus Acenocumarol for the Prevention of Stroke in Atrial Fibrillation. Budget Impact Analysis in one Health Department in Spain
spellingShingle Dabigatran versus Acenocumarol for the Prevention of Stroke in Atrial Fibrillation. Budget Impact Analysis in one Health Department in Spain
Pla, AB
Anticoagulant
Dabigetran
Acenocoumarol
Health Care Costs
Atrial fibrillation
Economics
title_short Dabigatran versus Acenocumarol for the Prevention of Stroke in Atrial Fibrillation. Budget Impact Analysis in one Health Department in Spain
title_full Dabigatran versus Acenocumarol for the Prevention of Stroke in Atrial Fibrillation. Budget Impact Analysis in one Health Department in Spain
title_fullStr Dabigatran versus Acenocumarol for the Prevention of Stroke in Atrial Fibrillation. Budget Impact Analysis in one Health Department in Spain
title_full_unstemmed Dabigatran versus Acenocumarol for the Prevention of Stroke in Atrial Fibrillation. Budget Impact Analysis in one Health Department in Spain
title_sort Dabigatran versus Acenocumarol for the Prevention of Stroke in Atrial Fibrillation. Budget Impact Analysis in one Health Department in Spain
dc.creator.none.fl_str_mv Pla, AB
Sóler, VG
Ridao-López, M
Pérez, JN
Cubells, BN
Peiró, S
author Pla, AB
author_facet Pla, AB
Sóler, VG
Ridao-López, M
Pérez, JN
Cubells, BN
Peiró, S
author_role author
author2 Sóler, VG
Ridao-López, M
Pérez, JN
Cubells, BN
Peiró, S
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Anticoagulant
Dabigetran
Acenocoumarol
Health Care Costs
Atrial fibrillation
Economics
topic Anticoagulant
Dabigetran
Acenocoumarol
Health Care Costs
Atrial fibrillation
Economics
description Background: To Estimate, in the context of a Health Department of the Valencia Health Agency, the budgetary impact of the widespread use of dabigatran at doses of 110 and 150 mg in patients with non-valvular atrial fibrillation (AF), regarding the current scenario with acenocoumarol therapy. Methods: Budget impact analysis of three scenarios of oral anticoagulation use in AF: a) current treatment with acenocoumarol, b) widespread replacement of acenocoumarol for Dabigatran 110 mg and, c) idem at doses of 150 mg. The analysis was conducted from the perspective of the Valencia Health Agency with a time horizon of one year (2009). The effectiveness and adverse effects were extrapolated from the RE-LY study, while prevalence and cost data correspond to the Health Department estimates in 2009. Results: We included 5889 patients (2.4% of the population > 18 years) diagnosed with AF, of which 3726 (63.2%) were treated with acenocoumarol. The total costs of each scenario were (sic) 1,119,412 (sic) 300 patient/year) for acenocoumarol, (sic) 4,985,095 (sic) 1,337 patient/year) for dabigatran 110 and (sic) 4,981,226 ((sic) 1,336 patient/year) for dabigatran 150, with a budget impact of 1,037 euros/year per patient shifted from acenocumarol to dabigatran-150. Conclusions: The high budgetary impact of moving to a scenario of widespread substitution of warfarin for Dabigatran supports the restriction of this therapeutic strategy to subgroups of patients at high risk or difficult control.
publishDate 2013
dc.date.none.fl_str_mv 2013
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/21081
url https://fisabio.portalinvestigacion.com/publicaciones/21081
dc.language.none.fl_str_mv Español
language_invalid_str_mv Español
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MINISTERIO DE SANIDAD Y CONSUMO
publisher.none.fl_str_mv MINISTERIO DE SANIDAD Y CONSUMO
dc.source.none.fl_str_mv Revista Espanola de Salud Publica
ISSN: 11355727
ISSNe: 21739110
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424517145690112
score 15,811543

Similares en LA Referencia